Standout Papers

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection 1998 2026 2007 2016 5.0k
  1. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection (2002)
    Michael Fried, Mitchell L. Shiffman et al. New England Journal of Medicine
  2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (2001)
    Michael P. Manns, John G. McHutchison et al. The Lancet
  3. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C (1998)
    John G. McHutchison, Stuart C. Gordon et al. New England Journal of Medicine
  4. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities (2001)
    Arun J. Sanyal, Faridoddin Mirshahi et al. Gastroenterology
  5. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C (1998)
    Gary L. Davis, Rafael Esteban et al. New England Journal of Medicine
  6. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values (2003)
    Melissa J. Contos, Carol Sargeant et al. Hepatology
  7. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection (2009)
    John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine
  8. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis (2000)
    E. Jenny Heathcote, Mitchell L. Shiffman et al. New England Journal of Medicine
  9. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis (2014)
    Fred Poordad, Christophe Hézode et al. New England Journal of Medicine
  10. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019)
    Arun J. Sanyal, Stephen A. Harrison et al. Hepatology
  11. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis (2019)
    Michael Trauner, Aliya Gulamhusein et al. Hepatology

Immediate Impact

9 by Nobel laureates 7 from Science/Nature 113 standout
Sub-graph 1 of 13

Citing Papers

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021 Standout
38 intermediate papers

Works of Mitchell L. Shiffman being referenced

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
2019 Standout
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C†
2007
and 13 more

Author Peers

Author Last Decade Papers Cites
Mitchell L. Shiffman 27265 27020 3005 269 33.5k
Zachary Goodman 30336 32446 4296 293 40.9k
Adrian M. Di Bisceglie 23261 23266 2203 380 32.6k
Thierry Poynard 33163 35335 4255 425 42.7k
Antonio Craxı̀ 19193 19269 2448 511 25.6k
Jay H. Hoofnagle 29585 29885 4086 388 42.8k
Eugene R. Schiff 22320 21998 2608 361 28.2k
John G. McHutchison 36416 32868 1651 459 42.6k
K. Rajender Reddy 27667 24323 5180 577 36.3k
Patrick Marcellin 33396 33397 1166 625 37.8k
Norah A. Terrault 19102 20430 3727 451 25.7k

All Works

Loading papers...

Rankless by CCL
2026